Standard smartphone technology can be adapted to screen skin lesions, providing a low-cost, accessible medical diagnostic tool for skin cancer, according to a new study.
Standard smartphone technology can be used as a simpler and low-cost tool to monitor melanoma and non-melanoma skin cancer, reports a new study. The findings of the study are published in the Journal of Biomedical Optics.// Skin lesions are diagnosed by a simple system of color, size, asymmetry, and surface appearance: the way in which the lesions are lit indicates differences between normal and malignant lesions.
‘Melanoma and non-melanoma skin cancer monitoring are feasible with polarized white-light imaging and polarized multispectral imaging using LED illumination and smartphone-based cameras.’
For their study, the authors developed two dermascopes using a smartphone-based camera and a USB-based camera. Both dermascopes, integrating LED-based polarized white-light imaging (PWLI), polarized multispectral imaging (PMSI) and image-processing algorithms, successfully mapped and delineated between the dermal chromophores indicative of melanoma, and the general skin redness known as erythema. According to JBO Editor-in-Chief, SPIE Fellow, and MacLean Professor of Engineering at Dartmouth Brian W. Pogue, leveraging a smartphone camera to image skin lesions improves both the efficiency and efficacy of skin-lesion diagnostics. "The functionality and performance for the detection of skin cancers are very important," he said.
"The cellphone camera approaches proposed and tested in this paper introduce key steps in a design that will provide simple, accurate diagnoses. While there are always ways to make medical imaging systems work, they can often be too expensive to be a viable commercial success. Similarly, devices can be made so complex that they aren't readily adopted. Here, the already-familiar platform is both low cost and intuitive to use. The simplicity of the approach here successfully combines the need for simple diagnostic tools with high precision. This is the kind of innovation that will potentially allow for easier adoption in clinical use."
Source-Eurekalert